Chimiothérapie néoadjuvante à base de cisplatine du cancer de la vessie : bientôt dépassée ? [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]

Details

Serval ID
serval:BIB_3BB8FA781224
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Chimiothérapie néoadjuvante à base de cisplatine du cancer de la vessie : bientôt dépassée ? [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]
Journal
Revue medicale suisse
Author(s)
Bosshard P., Roth B.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
27/11/2019
Peer-reviewed
Oui
Volume
15
Number
673
Pages
2190-2194
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
For more than 30 years, cisplatin-based neoadjuvant chemotherapy (NAC) has been administered to patients with muscle-invasive bladder cancer (MIBC). However, the benefit is modest. With the advent of modern immunotherapies, new therapeutic strategies are also opening up to bladder cancer. Unfortunately, the initial results in the neoadjuvant context show a response rate of only 20-35 %. Other therapeutic strategies, such as Pan-FGFR inhibitors, do not show better response. Due to the high genetic variability of bladder cancer, a « one drug fits all » concept is not an ideal solution. Patient selection based on the probability of response appears to be a promising strategy to improve this modest benefit of each treatment. In this context, the NAC will also continue to play an important role.
Keywords
Chemotherapy, Adjuvant, Cisplatin/therapeutic use, Humans, Immunotherapy/trends, Neoadjuvant Therapy/trends, Neoplasm Invasiveness, Patient Selection, Urinary Bladder Neoplasms/drug therapy, Urinary Bladder Neoplasms/pathology
Pubmed
Create date
08/01/2021 19:25
Last modification date
09/01/2021 6:26
Usage data